GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Acyclovir

GlobalRPh source pageBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Zovirax

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

UCSF - oral acyclovir: HSV and VZV

Product / population
Adults; oral acyclovir only.
Renal measure
CrCl in mL/min where specified; no equation inferred.

Dosing / renal protocol and limits

Limits that apply to these rows

Dialysis recommendations use limited data and expert opinion. The source advises considering an additional post-HD dose. Oral and IV protocols are not interchangeable.

Initial HSV - oral
CrCl, mL/minSource-specific dose / instruction
>25400 mg every 8 hours
10-25400 mg every 8 hours
<10200 mg every 12 hours
Mild VZV - oral
CrCl, mL/minSource-specific dose / instruction
>25800 mg five times daily
10-25800 mg every 8 hours
<10400 mg every 12 hours
Dialysis guidance - separate source-specific schedules
Oral acyclovir - dialysis
Dialysis setting / indicationSource-specific schedule
Intermittent HD - initial/recurrent HSV200 mg every 12 hours
Intermittent HD - VZV400 mg every 12 hours
Intermittent HD - suppression/prophylaxis200 mg every 12 hours
Continuous HD - initial HSV400 mg every 8 hours
Continuous HD - recurrent HSV or prophylaxis400 mg every 12 hours
Continuous HD - VZV800 mg five times daily
Read the retained text before reformatting

CrCl >25 / 10-25 / <10 mL/min: initial HSV uses 400 mg orally every 8 hours / 400 mg every 8 hours / 200 mg every 12 hours. Mild VZV uses 800 mg five times daily / 800 mg every 8 hours / 400 mg every 12 hours.

Intermittent HD: initial or recurrent HSV 200 mg every 12 hours; VZV 400 mg every 12 hours; suppression/prophylaxis 200 mg every 12 hours. Continuous HD: initial HSV 400 mg every 8 hours; recurrent HSV 400 mg every 12 hours; VZV 800 mg five times daily; prophylaxis 400 mg every 12 hours.

Dialysis recommendations are based on limited data and expert opinion. The page advises consideration of an additional post-HD dose. Do not transfer these oral regimens to IV acyclovir.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/acyclovir-po

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - acyclovir intravenous: HSV, VZV and dialysis

Adults; IV acyclovir only. Separate from oral and topical formulations.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeUCSF - acyclovir intravenous: HSV, VZV and dialysisUCSF - oral acyclovir: HSV and VZV
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The original page contains two different IV renal band sets (25/50 versus 30/50) and an indexed CrCl table. They are preserved separately, not reconciled into one recommendation. Confirm the applicable current product label before clinical use.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/acyclovir/

Usual Dosing (Adults)

Mucocutaneous herpes simplex: IV: 5 mg/kg/dose every 8 hours x 5-10 days.

Encephalitis: 10mg/kg/dose IV every 8 hours.

Primary HSV infection-genital (Oral therapy): 200mg every 4 hours while awake (5 times/day) or 400mg orally three times daily for 10 days.

Recurrent genital: 400mg orally three times daily for 5 days.

Herpes Zoster: 800mg orally every 4 hours while awake (5 times/day) for 7 days. If severe give 10-12 mg/kg IV every 8 hours x 7-14 days.

Chronic suppression (genital herpes): 400mg orally twice daily.

GRPH-acyclovir-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing - source table

Patients with Acute or Chronic Renal Impairment: Refer to dosing info above for recommended doses, and adjust the dosing interval as indicated in the Table below.

Creatinine clearance (mL/min/1.73 m2)Percent of recommended doseDosing interval (hours)
>50100%8
25-50100%12
10-25100%24
0-1050%24
GRPH-acyclovir-02 · Source section: Renal Dosing - source tableRenal section finder

Renal Dosing - additional source comments

Oral:

Genital herpes therapy:

[>=10]: Usual dose

[<10 ml/min]: 200mg q12h

Genital herpes suppression/prophylaxis:

[>=10]: Usual dose

[<10 ml/min]: 200mg q12h

Herpes zoster:

[>25 ml/min]: Usual dose

[10-25]: 800mg q8h

[<10 ml/min]: 800mg q12h

IV:

[>50 ml/min]: No change

[30-50]: 5-10mg/kg q12h

[10-30]: 5-10mg/kg q24h

[<10 ml/min]: 2.5 to 5mg/kg q24h

GRPH-acyclovir-03 · Source section: Renal Dosing - additional source commentsRenal section finder

Hemodialysis

Hemodialysis: For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a 6 hour dialysis period. Therefore, the patient's dosing schedule should be adjusted so that an additional dose is administered after each dialysis.

Peritoneal Dialysis: No supplemental dose appears to be necessary after adjustment of the dosing interval.

IV: 2.5-5 mg/kg IV q24h (give dose after dialysis on dialysis days).

Oral: See above for <10 ml/min.

GRPH-acyclovir-04 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

UCSF - acyclovir intravenous: HSV, VZV and dialysis

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; IV acyclovir only. Separate from oral and topical formulations.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

The printed bands overlap at exactly 25. Do not choose a boundary by assumption.

UCSF uses actual weight unless above 120% of ideal, then adjusted weight; this differs from ideal-weight labeling in obesity. These are IV regimens. Reassess dialysis prescription and residual function.

Non-CNS HSV - IV
CrCl, mL/minSource-specific dose / instruction
>505 mg/kg every 8 hours
25-505 mg/kg every 12 hours
10-255 mg/kg every 24 hours
<102.5 mg/kg every 24 hours
Encephalitis or disseminated VZV - IV
CrCl, mL/minSource-specific dose / instruction
>5010 mg/kg every 8 hours
25-5010 mg/kg every 12 hours
10-2510 mg/kg every 24 hours
<105 mg/kg every 24 hours
Dialysis guidance - separate source-specific schedules
IV acyclovir - dialysis
Dialysis setting / indicationSource-specific schedule
Intermittent HD - non-CNS HSV2.5 mg/kg initially and each evening
Intermittent HD - encephalitis/disseminated VZV5 mg/kg initially and each evening
Continuous HD - non-CNS HSV5 mg/kg every 24 hours
Continuous HD - encephalitis/disseminated VZV10 mg/kg every 12 hours
Read the retained text before reformatting

CrCl >50 / 25-50 / 10-25 / <10 mL/min: non-CNS HSV uses 5 mg/kg IV every 8 / 12 / 24 hours, then 2.5 mg/kg daily in the lowest band. Encephalitis or disseminated VZV uses 10 mg/kg every 8 / 12 / 24 hours, then 5 mg/kg daily. The source overlaps at exactly 25.

Intermittent HD: non-CNS HSV 2.5 mg/kg initially and each evening; encephalitis/disseminated VZV 5 mg/kg initially and each evening. Continuous HD: non-CNS HSV 5 mg/kg daily; encephalitis/disseminated VZV 10 mg/kg every 12 hours.

UCSF uses actual weight unless above 120% of ideal, then adjusted weight; its discussion acknowledges disagreement with ideal-weight labeling for obesity. These are institutional IV regimens, not oral dosing. Dialysis prescription and residual function can materially change requirements.

RDM30-033-acyclovir-1 · Source locator: UCSF - acyclovir intravenous: HSV, VZV and dialysis; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/acyclovir-iv
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
61d7d1340be3d6cc8b1efd4632bea4d0f6a1bfa238a168afd8ed36485114830f
Professional

UCSF - oral acyclovir: HSV and VZV

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; oral acyclovir only.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Dialysis recommendations use limited data and expert opinion. The source advises considering an additional post-HD dose. Oral and IV protocols are not interchangeable.

Initial HSV - oral
CrCl, mL/minSource-specific dose / instruction
>25400 mg every 8 hours
10-25400 mg every 8 hours
<10200 mg every 12 hours
Mild VZV - oral
CrCl, mL/minSource-specific dose / instruction
>25800 mg five times daily
10-25800 mg every 8 hours
<10400 mg every 12 hours
Dialysis guidance - separate source-specific schedules
Oral acyclovir - dialysis
Dialysis setting / indicationSource-specific schedule
Intermittent HD - initial/recurrent HSV200 mg every 12 hours
Intermittent HD - VZV400 mg every 12 hours
Intermittent HD - suppression/prophylaxis200 mg every 12 hours
Continuous HD - initial HSV400 mg every 8 hours
Continuous HD - recurrent HSV or prophylaxis400 mg every 12 hours
Continuous HD - VZV800 mg five times daily
Read the retained text before reformatting

CrCl >25 / 10-25 / <10 mL/min: initial HSV uses 400 mg orally every 8 hours / 400 mg every 8 hours / 200 mg every 12 hours. Mild VZV uses 800 mg five times daily / 800 mg every 8 hours / 400 mg every 12 hours.

Intermittent HD: initial or recurrent HSV 200 mg every 12 hours; VZV 400 mg every 12 hours; suppression/prophylaxis 200 mg every 12 hours. Continuous HD: initial HSV 400 mg every 8 hours; recurrent HSV 400 mg every 12 hours; VZV 800 mg five times daily; prophylaxis 400 mg every 12 hours.

Dialysis recommendations are based on limited data and expert opinion. The page advises consideration of an additional post-HD dose. Do not transfer these oral regimens to IV acyclovir.

RDM30-034-acyclovir-1 · Source locator: UCSF - oral acyclovir: HSV and VZV; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/acyclovir-po
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
1f8d13a14936675e7bd7efd67575054745ed11ae3dc4aa5a81cfc7233bb7bccf

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/acyclovir/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
c0bfd53ee69ef52c462ff8ea245d27494897df58b0d17edeabed970ffaf2cfb1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report